In a major stride toward advancing chronic care, Cipla has joined hands with Eli Lilly and Company to expand access to the groundbreaking diabetes and weight-loss therapy tirzepatide in India. Under the partnership, Cipla will market the therapy under the new brand name Yurpeak, while Lilly continues manufacturing the molecule.

The launch of Yurpeak marks a pivotal moment in India’s fight against type 2 diabetes and obesity, conditions that affect millions nationwide. Available in six dosage strengths (2.5 mg to 15 mg) as a once-weekly prefilled pen, Yurpeak mirrors Lilly’s original brand and will be priced identically, ensuring affordability and accessibility.

Cipla’s vast distribution network, particularly across non-metro regions, will help bring this innovative treatment to a broader population base. “The introduction of a second brand of tirzepatide through this agreement with Cipla reinforces Lilly’s commitment to expanding access to chronic care innovation,” said Winselow Tucker, President and General Manager, Lilly India.

This collaboration signifies more than a commercial tie-up, it represents a fusion of global innovation with India’s healthcare reach, redefining access, scale, and impact in chronic disease management.